Long B, Wang Y, Hao S, Shi G
Am J Cancer Res. 2024; 14(9):4633-4651.
PMID: 39417189
PMC: 11477815.
DOI: 10.62347/KMWB5164.
Silva-Carvalho A, Filiu-Braga L, Bogea G, de Assis A, Pittella-Silva F, Saldanha-Araujo F
Cancer Cell Int. 2024; 24(1):243.
PMID: 38997742
PMC: 11249034.
DOI: 10.1186/s12935-024-03441-y.
Hu X, Wang Z, Qin Y, Xu J, Xu N, Wang Q
Bone Marrow Transplant. 2024; 59(8):1146-1153.
PMID: 38769349
DOI: 10.1038/s41409-024-02306-2.
Schierbeck F, Mortensen J, Andersen N, Friis L, Kornblit B, Petersen S
Eur J Haematol. 2022; 110(1):50-59.
PMID: 36153797
PMC: 10092052.
DOI: 10.1111/ejh.13869.
Fawzy M, Abd El-hafez A, El-Ashwah S, Abouzeid T, Waheeb M, Saif M
Asian Pac J Cancer Prev. 2021; 22(7):2143-2152.
PMID: 34319037
PMC: 8607084.
DOI: 10.31557/APJCP.2021.22.7.2143.
DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database.
Qiu K, Liao X, He Z, Wu R, Li Y, Xu L
BMC Cancer. 2021; 21(1):813.
PMID: 34266412
PMC: 8283927.
DOI: 10.1186/s12885-021-08545-6.
Correlation analysis of long non-coding RNA TUG1 with disease risk, clinical characteristics, treatment response, and survival profiles of adult Ph Acute lymphoblastic leukemia.
Zeng P, Chai Y, You C, Yue L, Wu C, Chen H
J Clin Lab Anal. 2021; 35(8):e23583.
PMID: 34251066
PMC: 8373340.
DOI: 10.1002/jcla.23583.
Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial.
Zhang B, Zhou J, Yu F, Lv T, Fang B, Fan D
Exp Hematol Oncol. 2020; 9:5.
PMID: 32280563
PMC: 7137207.
DOI: 10.1186/s40164-020-00162-6.
Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL.
Li S, Fan Q, Xu L, Wang Y, Zhang X, Chen H
Front Oncol. 2020; 10:320.
PMID: 32257948
PMC: 7089930.
DOI: 10.3389/fonc.2020.00320.
Cyclophosphamide for the treatment of acute lymphoblastic leukemia: A protocol for systematic review.
Zhao Y, Song H, Ni L
Medicine (Baltimore). 2019; 98(5):e14293.
PMID: 30702599
PMC: 6380740.
DOI: 10.1097/MD.0000000000014293.
Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
Assaf N, El-Cheikh J, Bazarbachi A, Salem Z, Farra C, Chakhachiro Z
Mol Biol Rep. 2019; 46(2):2003-2011.
PMID: 30701458
DOI: 10.1007/s11033-019-04649-2.
Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment.
Wolfson J, Richman J, Sun C, Landier W, Leung K, Smith E
Cancer Epidemiol Biomarkers Prev. 2018; 27(10):1133-1141.
PMID: 30262597
PMC: 6238217.
DOI: 10.1158/1055-9965.EPI-18-0430.
Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway.
Duan Y, Dong X, Nie J, Li P, Lu F, Ma D
Oncol Lett. 2018; 16(4):5473-5481.
PMID: 30250620
PMC: 6144465.
DOI: 10.3892/ol.2018.9291.
Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis.
Shen Z, Gu X, Mao W, Yin L, Yang L, Zhang Z
BMC Cancer. 2018; 18(1):755.
PMID: 30037340
PMC: 6056932.
DOI: 10.1186/s12885-018-4670-5.
Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M
Pharmacoeconomics. 2018; 36(7):759-768.
PMID: 29502175
DOI: 10.1007/s40273-018-0624-7.
Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.
Wolfson J, Sun C, Wyatt L, Stock W, Bhatia S
Cancer Epidemiol Biomarkers Prev. 2017; 26(3):312-320.
PMID: 28209594
PMC: 5546404.
DOI: 10.1158/1055-9965.EPI-16-0722.
Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.
Huang Z, Tong H, Li Y, Qian J, Wang J, Wang Z
Med Sci Monit. 2016; 22:4967-4973.
PMID: 27987364
PMC: 5189722.
DOI: 10.12659/msm.899021.
Targeting the TAM Receptors in Leukemia.
Huey M, Minson K, Earp H, DeRyckere D, Graham D
Cancers (Basel). 2016; 8(11).
PMID: 27834816
PMC: 5126761.
DOI: 10.3390/cancers8110101.
Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.
Evers D, Zwaginga J, Tijmensen J, Middelburg R, de Haas M, de Vooght K
Haematologica. 2016; 102(1):52-59.
PMID: 27634204
PMC: 5210232.
DOI: 10.3324/haematol.2016.152074.
The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
Fedorov V, Upadhyay V, Fathi A
Curr Hematol Malig Rep. 2016; 11(3):165-74.
PMID: 26939921
DOI: 10.1007/s11899-016-0316-3.
